Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside? [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
If you are wondering whether Sarepta Therapeutics' current share price offers value or just fresh risk, you are not alone. After a very steep 82.1% share price decline over the last year and a 4.6% fall year to date, many investors are reassessing what the recent price level really implies about future expectations. Recent news coverage around Sarepta has focused on regulatory and product pipeline developments alongside changing sentiment in the biotech sector, which helps explain part of the sharp move in the share price. These headlines have pushed investors to reassess both the risk profile and what they are willing to pay for the stock today. On our valuation checklist, Sarepta scores 5 out of 6 for being undervalued, giving it a value score of . Next, we will compare different valuation approaches before finishing with a more holistic way to think about what the stock might be worth. Find out why Sarepta Therapeutics's -82.1% return over the last year is lagging behind i
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s DiseaseBusiness Wire
- Sarepta's Elevidys Data Underscore Long Term Duchenne Therapy Durability [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $20.00 price target on the stock.MarketBeat
- Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 1/29/26 - Form 4
- 1/29/26 - Form 4
- 1/21/26 - Form SCHEDULE
- SRPT's page on the SEC website